Gamida Cell Ltd.

The analytical tools encompassed by the concept of real-world evidence are growing increasingly valuable for enhancing early-stage drug development, an area receiving less attention than pivotal trial

Commercializing cell and gene therapies is a major problem for manufacturers, even if their products have proven successful in clinical studies. For companies whose therapies do make it to the market,

Cell and gene therapy developers have focused clinical programs around specific regulators in the absence of uniform global standards, with few sponsors successfully attempting approvals in both the U

The US Food and Drug Administration beats the European Medicines Agency to approval of novel agents across the board, but the imbalance is even more stark in oncology, the largest therapy area, a Pin